The CCL8 antibody targets the chemokine (C-C motif) ligand 8 (CCL8), a small cytokine belonging to the CC chemokine family. Also known as monocyte chemoattractant protein-2 (MCP-2), CCL8 is secreted by immune cells, including monocytes, macrophages, and T cells, and plays a role in recruiting leukocytes to sites of inflammation or infection. It binds to chemokine receptors such as CCR1. CCR2. CCR3. and CCR5. mediating immune responses in conditions like chronic inflammation, autoimmune diseases, and cancer. Dysregulated CCL8 expression is linked to pathological processes, including tumor progression and viral infections (e.g., HIV).
CCL8 antibodies are essential tools for detecting and quantifying CCL8 in research settings. They are widely used in techniques like Western blotting, ELISA, immunohistochemistry, and flow cytometry to study CCL8's expression, localization, and function in cellular and tissue models. These antibodies aid in elucidating CCL8's role in disease mechanisms, such as its pro-tumorigenic effects in the tumor microenvironment or its contribution to inflammatory disorders. Commercially available CCL8 antibodies are typically developed in hosts like rabbits or mice, with validation for specificity and sensitivity across applications. Their use supports drug discovery and biomarker studies, particularly in immunology and oncology research.